Defining MAP3 kinases required for MDA-MB-231 cell tumor growth and metastasis

Oncogene

Volumn 31, Issue 34, 2012, Pages 3889-3900

  Cronan, M R ^a   Nakamura, K ^a   Johnson, N L ^a   Granger, D A ^a   Cuevas, B D ^b   Wang, J G ^a   MacKman, N ^a   Scott, J E ^c   Dohlman, H G ^a   Johnson, G L ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

^c NORTH CAROLINA CENTRAL UNIVERSITY   (United States)

Author keywords

MAP3K; MAPK network; MEKK2; metastasis; MLK3

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 2; MIXED LINEAGE KINASE 3; SHORT HAIRPIN RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CANCER SIZE; CARCINOGENESIS; CELL PROLIFERATION; CELL STRAIN MDA MB 231; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; IN VITRO STUDY; LYMPH NODE METASTASIS; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; HEK293 CELLS; HUMANS; ISOENZYMES; MAMMARY NEOPLASMS, EXPERIMENTAL; MAP KINASE KINASE KINASE 2; MAP KINASE KINASE KINASES; MICE; MICE, SCID; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NEOPLASM METASTASIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRANSPLANTATION, HETEROLOGOUS; TUMOR BURDEN;

MUS;

EID: 84865441425     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.544     Document Type: Article

References (44)

1. Al-Nedawi K, Meehan B, Micallef J, Lhotak V, May L, Guha A et al. (2008). Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol 10: 619-624. (Pubitemid 351627382)
2. Brancho D, Ventura JJ, Jaeschke A, Doran B, Flavell RA, Davis RJ. (2005). Role of MLK3 in the regulation of mitogen-activated protein kinase signaling cascades. Mol Cell Biol 25: 3670-3681. (Pubitemid 40559573)
3. Cazares LH, Troyer D, Mendrinos S, Lance RA, Nyalwidhe JO, Beydoun HA et al. (2009). Imaging mass spectrometry of a specific fragment of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase 2 discriminates cancer from uninvolved prostate tissue. Clin Cancer Res 15: 5541-5551.
4. Cha H, Dangi S, Machamer CE, Shapiro P. (2006). Inhibition of mixed-lineage kinase (MLK) activity during G2-phase disrupts microtubule formation and mitotic progression in HeLa cells. Cell Signal 18: 93-104. (Pubitemid 41415718)
5. Chandana SR, Leece CM, Gallo KA, Madhukar BV, Conley BA. (2010). Inhibition of MLK3 decreases proliferation and increases antiproliferative activity of epidermal growth factor receptor (EGFR) inhibitor in pancreatic cancer cell lines. Cancer Growth Metast 2010: 1.
6. Chen J, Miller EM, Gallo KA. (2010). MLK3 is critical for breast cancer cell migration and promotes a malignant phenotype in mammary epithelial cells. Oncogene 29: 4399-4411.
7. Cuevas BD, Abell AN, Johnson GL. (2007). Role of mitogen-activated protein kinase kinase kinases in signal integration. Oncogene 26: 3159-3171. (Pubitemid 46763012)
8. Cuevas BD, Winter-Vann AM, Johnson NL, Johnson GL. (2006). MEKK1 controls matrix degradation and tumor cell dissemination during metastasis of polyoma middle-T driven mammary cancer. Oncogene 25: 4998-5010.
9. Davidson B, Konstantinovsky S, Kleinberg L, Nguyen MT, Bassarova A, Kvalheim G et al. (2006). The mitogen-activated protein kinases (MAPK) p38 and JNK are markers of tumor progression in breast carcinoma. Gynecol Oncol 102: 453-461. (Pubitemid 44376656)
10. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al. (2002). Mutations of the BRAF gene in human cancer. Nature 417: 949-954. (Pubitemid 34716871)
11. Ding L, Ellis MJ, Li S, Larson DE, Chen K, Wallis JW et al. (2010). Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464: 999-1005.
12. Fedorov O, Muller S, Knapp S. (2010). The (un)targeted cancer kinome. Nat Chem Biol 6: 166-169.
13. Fodde R, Kuipers J, Rosenberg C, Smits R, Kielman M, Gaspar C et al. (2001). Mutations in the APC tumour suppressor gene cause chromosomal instability. Nat Cell Biol 3: 433-438. (Pubitemid 32288454)
14. Guo Z, Clydesdale G, Cheng J, Kim K, Gan L, McConkey DJ et al. (2002). Disruption of Mekk2 in mice reveals an unexpected role for MEKK2 in modulating T-cell receptor signal transduction. Mol Cell Biol 22: 5761-5768. (Pubitemid 34815825)
15. Hui L, Zatloukal K, Scheuch H, Stepniak E, Wagner EF. (2008). Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation. J Clin Invest 118: 3943-3953.
16. Husemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, Burghart E et al. (2008). Systemic spread is an early step in breast cancer. Cancer Cell 13: 58-68. (Pubitemid 350309740)
17. Jaeschke A, Davis RJ. (2007). Metabolic stress signaling mediated by mixed-lineage kinases. Mol Cell 27: 498-508. (Pubitemid 47126942)
18. Kasthuri RS, Taubman MB, Mackman N. (2009). Role of tissue factor in cancer. J Clin Oncol 27: 4834-4838.
19. Kesavan K, Lobel-Rice K, Sun W, Lapadat R, Webb S, Johnson GL et al. (2004). MEKK2 regulates the coordinate activation of ERK5 and JNK in response to FGF-2 in fibroblasts. J Cell Physiol 199: 140-148. (Pubitemid 38197522)
20. Khorana AA, Francis CW, Menzies KE, Wang JG, Hyrien O, Hathcock J et al. (2008). Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer. J Thromb Haemost 6: 1983-1985.
21. Kim KY, Kim BC, Xu Z, Kim SJ. (2004). Mixed lineage kinase 3 (MLK3)-activated p38 MAP kinase mediates transforming growth factor-beta-induced apoptosis in hepatoma cells. J Biol Chem 279: 29478-29484. (Pubitemid 38915827)
22. Lee W, Jiang Z, Liu J, Haverty PM, Guan Y, Stinson J et al. (2010). The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature 465: 473-477.
23. McCracken SR, Ramsay A, Heer R, Mathers ME, Jenkins BL, Edwards J et al. (2008). Aberrant expression of extracellular signal-regulated kinase 5 in human prostate cancer. Oncogene 27: 2978-2988. (Pubitemid 351668010)
24. Mehta PB, Jenkins BL, McCarthy L, Thilak L, Robson CN, Neal DE et al. (2003). MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion. Oncogene 22: 1381-1389. (Pubitemid 36384600)
25. Mishra R, Barthwal MK, Sondarva G, Rana B, Wong L, Chatterjee M et al. (2007). Glycogen synthase kinase-3beta induces neuronal cell death via direct phosphorylation of mixed lineage kinase 3. J Biol Chem 282: 30393-30405. (Pubitemid 350035219)
26. Montero JC, Ocana A, Abad M, Ortiz-Ruiz MJ, Pandiella A, Esparis-Ogando A. (2009). Expression of Erk5 in early stage breast cancer and association with disease free survival identifies this kinase as a potential therapeutic target. PLoS One 4: e5565.
27. Nakamura K, Kimple AJ, Siderovski DP, Johnson GL. (2010). PB1 domain interaction of p62/sequestosome 1 and MEKK3 regulates NF-kappaB activation. J Biol Chem 285: 2077-2089.
28. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI et al. (2010). Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 12: R68.
29. Rak J. (2010). Microparticles in cancer. Semin Thromb Hemost 36: 888-906.
30. Samowitz WS, Sweeney C, Herrick J, Albertsen H, Levin TR, Murtaugh MA et al. (2005). Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 65: 6063-6069.
31. Sartorius CA, Shen T, Horwitz KB. (2003). Progesterone receptors A and B differentially affect the growth of estrogen-dependent human breast tumor xenografts. Breast Cancer Res Treat 79: 287-299. (Pubitemid 36750936)
32. Sheridan C, Brumatti G, Martin SJ. (2008). Oncogenic B-RafV600E inhibits apoptosis and promotes ERK-dependent inactivation of Bad and Bim. J Biol Chem 283: 22128-22135.
33. Sidebottom E, Clark SR. (1983). Cell fusion segregates progressive growth from metastasis. Br J Cancer 47: 399-406. (Pubitemid 13117147)
34. Sourvinos G, Tsatsanis C, Spandidos DA. (1999). Overexpression of the Tpl-2/Cot oncogene in human breast cancer. Oncogene 18: 4968-4973. (Pubitemid 29425303)
35. Sticht C, Freier K, Knopfle K, Flechtenmacher C, Pungs S, Hofele C et al. (2008). Activation of MAP kinase signaling through ERK5 but not ERK1 expression is associated with lymph node metastases in oral squamous cell carcinoma (OSCC). Neoplasia 10: 462-470. (Pubitemid 351657388)
36. Sun W, Wei X, Kesavan K, Garrington TP, Fan R, Mei J et al. (2003). MEK kinase 2 and the adaptor protein Lad regulate extracellular signal-regulated kinase 5 activation by epidermal growth factor via Src. Mol Cell Biol 23: 2298-2308. (Pubitemid 36351013)
37. Tatake RJ, O'Neill MM, Kennedy CA, Wayne AL, Jakes S, Wu D et al. (2008). Identification of pharmacological inhibitors of the MEK5/ERK5 pathway. Biochem Biophys Res Commun 377: 120-125.
38. Wagner EF, Nebreda AR. (2009). Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 9: 537-549.
39. Waldmeier P, Bozyczko-Coyne D, Williams M, Vaught JL. (2006). Recent clinical failures in Parkinson's disease with apoptosis inhibitors underline the need for a paradigm shift in drug discovery for neurodegenerative diseases. Biochem Pharmacol 72: 1197-1206. (Pubitemid 44604283)
40. Wang X, Chao L, Li X, Ma G, Chen L, Zang Y et al. (2010). Elevated expression of phosphorylated c-Jun NH2-terminal kinase in basal-like and 'triple-negative' breast cancers. Hum Pathol 41: 401-406.
41. Wo JY, Chen K, Neville BA, Lin NU, Punglia RS. (2011). Effect of very small tumor size on cancer-specific mortality in node-positive breast cancer. J Clin Oncoly 29: 2619-2627.
42. Yang Q, Deng X, Lu B, Cameron M, Fearns C, Patricelli MP et al. (2010). Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein. Cancer Cell 18: 258-267.
43. Yu JL, May L, Lhotak V, Shahrzad S, Shirasawa S, Weitz JI et al. (2005). Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood 105: 1734-1741. (Pubitemid 40223697)
44. Zen K, Yasui K, Nakajima T, Zen Y, Gen Y, Mitsuyoshi H et al. (2009). ERK5 is a target for gene amplification at 17p11 and promotes cell growth in hepatocellular carcinoma by regulating mitotic entry. Genes Chromosomes Cancer 48: 109-120.